Last reviewed · How we verify
Activated NK
At a glance
| Generic name | Activated NK |
|---|---|
| Sponsor | Xuanwu Hospital, Beijing |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Febrile neutropenia
- Febrile Neutropenia
- Hypokalemia
- Lymphocyte count decreased
- Neutrophil count decreased
- Anemia
- Platelet count decreased
- White blood cell decreased
- Hypophosphatemia
- Mucositis oral
- Nausea
- Hyperglycemia
Key clinical trials
- Study of DF1001 in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma (PHASE2)
- Intraperitoneal SK-NK Cell Injection for Advanced Ovarian Cancer With Massive Ascites (PHASE1, PHASE2)
- Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma (PHASE2)
- IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed (PHASE3)
- Effect of 0° and 50° N-K Table Load Angles on Quadriceps Activation in Knee Osteoarthritis (NA)
- Study of INKmune in Patients With mCRPC (CaRe Prostate) (PHASE1, PHASE2)
- A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Activated NK CI brief — competitive landscape report
- Activated NK updates RSS · CI watch RSS
- Xuanwu Hospital, Beijing portfolio CI